In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
TipRanks on MSN
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt
InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Life Extension reports on 15 science-backed longevity supplements to enhance lifespan and health, emphasizing the importance ...
Zacks Investment Research on MSN
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...
Silverback AI Chatbot has announced ongoing development and refinement of its AI Assistant feature, reflecting significant shifts in how organizations manage digital communication, user interaction, ...
To continuously observe how China is perceived by the world, the Global Times once again launched the "Global Survey on Impression and Understanding of China," covering 46 countries and about 51,700 ...
To continuously observe how China is perceived by the world, the Global Times once again launched the "Global Survey on ...
As the world enters 2026, global supply chains are fracturing once again, not from sudden shock but from sustained structural ...
For South Carolina residents, Miracle Hill isn’t just a store – it’s a community institution, a budget-stretcher, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback